Results 221 to 230 of about 192,929 (363)

Pharmacokinetics, safety, tolerability and fluorescence imaging of nizaracianine triflutate administered in three divided doses to healthy volunteers

British Journal of Clinical Pharmacology, EarlyView.
Aim Fluorescence‐guided surgery enhances intraoperative visualization of anatomical structures. Nizaracianine is a near‐infrared fluorescent agent that is exclusively renally cleared in animal models. It enables real‐time ureteral imaging and identification, potentially reduces risk of injury and facilitates assessment before surgical closure.
Lisanne K. A. Neijenhuis, Cedric M. W. Pesch, John V. Frangioni, Alexander L. Vahrmeijer, Jacobus Burggraaf, Naomi B. Klarenbeek   +5 more
wiley   +1 more source

The impact of data protection laws on Chinese digital cross-border mergers and acquisitions: A quasi-natural experiment based on the EU's general data protection regulation. [PDF]

PLoS One
Yu M, Ye X.
europepmc   +1 more source

THE ARCHITECTURE OF EU COMPANY LAW PROVISIONS PROTECTING WHO, WHAT AND HOW?

, 2015
Lela Mélon
openalex   +1 more source

U.S. Subpoenas and European data protection legislation : On conflicts of law in case of compliance by multinational companies with US Subpoenas from US Supervisory Authorities and EU data protection legislation [PDF]

, 2009
E.M.L. Moerel, Nani Jansen, Jeroen Koëter   +2 more
openalex  

European Company Law Experts' Response to the European Commission’s Green Paper 'The EU Corporate Governance Framework'

, 2011
Paul Davies, Klaus J. Hopt, Guido Ferrarini, Alain Pietrancosta, Rolf Skog, Stanisław Sołtysiński, Jaap Winter, Eddy Wymeersch   +7 more
openalex   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

Semantic clause retrieval for trademark law using transformer encoders and lexical baselines: a cross-domain agri-robotics compliance case study. [PDF]

Sci Rep
Asfand E Yar M, Hashir Q, Tanveer MH, Voicu RC, Khalid A.   +4 more
europepmc   +1 more source

Rapport tchèque - Modernization and Simplification of Private Companies Law among the EU Members States

, 2015
B. (Bohumil) Havel
openalex   +1 more source

Company Criminal Liability for Unlawful Attacks against Information Systems within the Scope of EU Law

, 2017
Kristtna BBezinovv
openalex   +1 more source

Zuranolone: A case study in (regulatory) rush to judgement?

British Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove, Milutin Kostic, Barbara Mintzes, Gianna D'Ambrozio, Allen Shaughnessy   +4 more
wiley   +1 more source